Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome

Clinical Cancer Research

Volumn 14, Issue 2, 2008, Pages 509-514

  Kurzrock, Razelle ^a   Kantarjian, Hagop M ^a   Blascovich, Michelle A ^b   Bucher, Cindy ^b   Verstovsek, Srdan ^a   Wright, John J ^c   Pilat, Susan R ^a   Cortes, Jorge E ^a   Estey, Elihu H ^a   Giles, Francis J ^a   Beran, Miloslav ^a   Sebti, Said M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FARNESYLTRANSFERASE; TIPIFARNIB;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATAXIA; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; ONCOGENE RAS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REMISSION; SIDE EFFECT; THROMBOCYTE;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; QUINOLONES;

EID: 38949159210     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1532     Document Type: Article

References (20)

1. Beaupre DM, Kurzrock R. Ras and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 1999;17:1071-9.
2. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 2000;275:30451-7.
3. Smets G. Xhonneux B, Cornelissen F, End D, Bowden C, Wouters W. R115777, a selective farnesyl protein transferase inhibitor (FTI), induces anti-angiogenic, apoptotic and anti-proliferative activity in CAPAN- and LoVo tumor xenografts [abstract 2170]. Proc Am Assoc Cancer Res 1998;39:318.
4. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratoryc orrelative trial. Blood 2001;97:3361-9.
5. Kurzrock R, Cortes J, Kantarjian H. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol 2002;39:20-4.
6. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 2003;102:4527-34.
7. Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004;22:1287-92.
8. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004;103:3271-7.
9. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003;101:1692-7.
10. Zimmerman TM, Harlin H, Odenike OM, et al. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractoryhema tologic malignancies. J Clin Oncol 2004;22:4816-22.
11. Crul M, de Klerk GJ, Swart M, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002;20:2726-35.
12. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
13. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
14. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
15. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25.
16. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk elderly patients with previously untreated acute myelogenous leukemia. Blood 2007;109:1387-94.
17. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007;109:4158-63.
18. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40.
19. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-803.
20. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57.